BioSpace

Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again

Despite meeting the primary endpoints in a Phase 3 trial, shares of Zealand Pharma dropped in premarket trading Thursday as the up to 9.8% weight loss reflected inferior loss to that generated by competitors.

作者 BioSpace

1 分钟阅读
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again

有活动行业的新闻要分享吗?

提交新闻稿或信息,触达数千名活动行业专业人士。

联系我们→

更多Health Tech相关内容

相关洞察